公开(公告)号：US20160361268A1

公开(公告)日：2016-12-15

申请号：US15142170

申请日：2016-04-29

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： Chih-Peng LIU ,  Ya-Chin LO ,  Ming-Cheng WEI ,  Maggie LU ,  Shuen-Hsiang CHOU ,  Shih-Ta CHEN ,  Hsiang-Wen TSENG

IPC: A61K9/51 ,  A61K33/24 ,  A61K9/00 ,  A61K31/282

CPC classification number: A61K9/5161 ,  A61K9/0019 ,  A61K31/555 ,  A61K33/24

Abstract: Disclosed is an intralymphatic delivery method for treating lymphatic cancer using hyaluronan nanoparticles. These nanoparticles include a hyaluronic acid derivative and a platinum compound. The hyaluronan derivative includes hyaluronic acid, modified histidine and optionally one or more of a polymer or a C4-C20 alkyl. The hyaluronic acid derivative may include linking group(s) that connect the polymer or the C4-C20 alkyl to the hyaluronic acid. The platinum compound includes dichloro(1,2-diaminocyclohexane) platinum (DACHPt), cisplatin and oxaliplatin. This intralymphatic delivery method offers significant advantages for the use of platinum medicines in treating lymphatic cancer.

Abstract translation: 公开了使用透明质酸纳米颗粒治疗淋巴癌的淋巴内递送方法。 这些纳米颗粒包括透明质酸衍生物和铂化合物。 透明质酸衍生物包括透明质酸，修饰的组氨酸和任选的一种或多种聚合物或C 4 -C 20烷基。 透明质酸衍生物可以包括连接聚合物或C4-C20烷基与透明质酸的连接基团。 铂化合物包括二氯（1,2-二氨基环己烷）铂（DACHPt），顺铂和奥沙利铂。 这种淋巴内递送方法在使用铂药物治疗淋巴癌方面具有显着的优势。

公开(公告)号：US20150111834A1

公开(公告)日：2015-04-23

申请号：US14488431

申请日：2014-09-17

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： Felice CHENG ,  Maggie J.M. LU ,  Yi-Ju KO ,  Min-Ying LIN ,  Shuen-Hsiang CHOU

IPC: A61K47/42 ,  A61K9/00 ,  A61K47/22 ,  A61K47/36 ,  A61K47/18

CPC classification number: A61K9/0048 ,  A61K9/0024 ,  A61K31/00 ,  A61K47/36

Abstract: The disclosure provides a recipe for in-situ gel, formed by dissolving at least one polymer and at least one gel prevention agent in a polar solvent to form a solution and placing the solution in a condition for in-situ forming gels. The disclosure also provides an implant and a drug delivery system formed by the recipe.

Abstract translation: 本公开提供了通过将至少一种聚合物和至少一种凝胶预防剂溶解在极性溶剂中形成溶液并将溶液置于用于原位形成凝胶的条件下形成的原位凝胶的配方。 本公开还提供了通过该配方形成的植入物和药物递送系统。

公开(公告)号：US20140199369A1

公开(公告)日：2014-07-17

申请号：US13926363

申请日：2013-06-25

Applicant: Industrial Technology Research Institute

Inventor： Maggie J.M. LU ,  Yu-Wen LO ,  Chih-Peng LIU ,  Chia-Wen HUANG ,  Po-Hung LAI ,  Tsan-Lin HU ,  Min-Ying LIN ,  Shuen-Hsiang CHOU ,  Chia-Mu TU

IPC: A61K47/36

CPC classification number: A61K47/36 ,  A61K9/0024 ,  A61K9/0085 ,  A61K9/127

Abstract: The disclosure provides a pharmaceutical composition. The pharmaceutical composition includes a chitosan with palmitoyl groups and an active agent. According to another embodiment, the pharmaceutical composition can further include a gelling accelerating agent. According to an embodiment of the disclosure, the active agent of the disclosure can be administered in the form of a nano-drug, liposome, micelle, or microparticle.

Abstract translation: 本公开提供药物组合物。 药物组合物包括具有棕榈酰基团的壳聚糖和活性剂。 根据另一个实施方案，药物组合物可以进一步包括胶凝加速剂。 根据本公开的实施方案，本公开的活性剂可以以纳米药物，脂质体，胶束或微粒的形式施用。